{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:14:57Z","timestamp":1790313297501,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.yebeh.2013.01.001","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T03:54:23Z","timestamp":1370836463000},"page":"S81-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"S1","title":["Management of juvenile myoclonic epilepsy"],"prefix":"10.1016","volume":"28","author":[{"given":"Arielle","family":"Crespel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gelisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Ferlazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Jerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Genton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2013.01.001_bb0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy: proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jnnp.70.2.240","article-title":"Clinical factors of drug resistance in juvenile myoclonic epilepsy","volume":"70","author":"Gelisse","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1034\/j.1600-0404.2001.00003.x","article-title":"Premature death in juvenile myoclonic epilepsy","volume":"104","author":"Genton","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1212\/WNL.34.3.285","article-title":"Juvenile myoclonic epilepsy of Janz","volume":"34","author":"Delgado-Escueta","year":"1984","journal-title":"Neurology"},{"issue":"Suppl. 4","key":"10.1016\/j.yebeh.2013.01.001_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1528-1157.1989.tb05833.x","article-title":"Juvenile myoclonic epilepsy: long-term response to therapy","volume":"30","author":"Penry","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0030","series-title":"Juvenile myoclonic epilepsy: the Janz syndrome","first-page":"11","article-title":"Juvenile myoclonic epilepsy today: current definition and limits","author":"Genton","year":"2000"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0035","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00007691-199902000-00014","article-title":"Valproate monotherapy in juvenile myoclonic epilepsy: dose-related effects on electroencephalographic and other neurophysiologic tests","volume":"21","author":"Sundqvist","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00007691-199804000-00004","article-title":"Valproate as monotherapy for juvenile myoclonic epilepsy: dose\u2013effect study","volume":"20","author":"Sundqvist","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1059-1311(96)80110-5","article-title":"The use of lamotrigine in juvenile myoclonic epilepsy","volume":"5","author":"Buchanan","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(97)00080-6","article-title":"Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide","volume":"29","author":"Wallace","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0060","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.yebeh.2004.04.002","article-title":"Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study","volume":"5","author":"Morris","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp.2010.217976","article-title":"When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy","volume":"10","author":"Nicolson","year":"2010","journal-title":"Pract Neurol"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0404.2010.01472.x","article-title":"Outcome of lamotrigine treatment in juvenile myoclonic epilepsy","volume":"124","author":"Bodenstein-Sachar","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0075","first-page":"75","article-title":"The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies","volume":"75","author":"Nicolson","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0080","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.yebeh.2013.01.001_bb0085","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ajmg.a.35438","article-title":"Antiepileptic drugs and pregnancy outcomes","volume":"158A","author":"Wlodarczyk","year":"2012","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0090","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/jnnp.2005.063750","article-title":"Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura","volume":"76","author":"Lampl","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.107.048504","article-title":"Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials","volume":"194","author":"Geddes","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-1211(96)00031-9","article-title":"Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam","volume":"25","author":"Kasteleijn-Nolst Tr\u00e9nit\u00e9","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton","year":"2000","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.seizure.2005.12.004","article-title":"Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study","volume":"15","author":"Labate","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2013.01.001_bb0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1528-1167.2007.01523.x","article-title":"Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy","volume":"49","author":"Specchio","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0125","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-8749.2007.02009.x","article-title":"Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents","volume":"50","author":"Verrotti","year":"2008","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2013.01.001_bb0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2007.07.001","article-title":"Levetiracetam monotherapy in juvenile myoclonic epilepsy","volume":"17","author":"Sharpe","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","article-title":"Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies","volume":"85","author":"Rosenfeld","year":"2009","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2013.01.001_bb0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11940-011-0131-z","article-title":"Treatment options in juvenile myoclonic epilepsy","volume":"13","author":"Mantoan","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0155","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/jnnp.66.6.759","article-title":"Topiramate in clinical practice: first year's post-licensing experience in a specialist epilepsy clinic","volume":"66","author":"Kellett","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0160","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/archneur.60.8.1100","article-title":"Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy","volume":"60","author":"Prasad","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0165","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.62.11.1705","article-title":"Topiramate in patients with juvenile myoclonic epilepsy","volume":"62","author":"Biton","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0170","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.yebeh.2007.03.003","article-title":"Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison","volume":"10","author":"Levisohn","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0175","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1590\/S0004-282X2005000500001","article-title":"Topiramate for the treatment of juvenile myoclonic epilepsy","volume":"63","author":"Sousa Pda","year":"2005","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0180","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.yebeh.2006.01.016","article-title":"Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate","volume":"8","author":"de Araujo Filho","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/j.1950-6945.2004.tb00075.x","article-title":"Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy","volume":"6","author":"Kothare","year":"2004","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0190","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.yebeh.2004.08.013","article-title":"Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy","volume":"5","author":"Szaflarski","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0195","first-page":"431","article-title":"Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series","volume":"100","author":"O'Rourke","year":"2007","journal-title":"Ir Med J"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/epd.2009.0239","article-title":"Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy","volume":"11","author":"Marinas","year":"2009","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF00242439","article-title":"Impulsiv petit mal","volume":"176","author":"Janz","year":"1957","journal-title":"Dtsch Z Nervenheilk"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002826-199012000-00001","article-title":"The neuropharmacology of juvenile myoclonic epilepsy","volume":"13","author":"Resor","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1059-1311(96)80062-8","article-title":"Methsuximide therapy of juvenile myoclonic epilepsy","volume":"5","author":"Hurst","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0220","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1528-1167.2005.04105.x","article-title":"Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy","volume":"46","author":"Khani","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0225","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1528-1157.1989.tb05479.x","article-title":"Clonazepam in juvenile myoclonic epilepsy","volume":"30","author":"Obeid","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0230","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.seizure.2011.12.010","article-title":"Lacosamide treatment of juvenile myoclonic epilepsy","volume":"21","author":"Afra","year":"2012","journal-title":"Seizure"},{"issue":"Suppl. 3","key":"10.1016\/j.yebeh.2013.01.001_bb0235","first-page":"66","article-title":"Juvenile myoclonic epilepsy: serious consequences due to pitfalls in diagnosis and management","volume":"36","author":"Kivity","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl. 4","key":"10.1016\/j.yebeh.2013.01.001_bb0240","first-page":"77","article-title":"Evaluation of various antiepileptic drugs in juvenile myoclonic epilepsy","volume":"37","author":"S\u00f6z\u00fcer","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0245","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1212\/WNL.55.8.1106","article-title":"Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?","volume":"55","author":"Genton","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0250","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1528-1157.2000.tb00258.x","article-title":"Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazepine","volume":"7","author":"Osorio","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0255","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.0013-9580.2004.19704.x","article-title":"Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies","volume":"45","author":"Gelisse","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0260","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1528-1157.1997.tb01107.x","article-title":"To the editor","volume":"38","author":"Carignani","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0265","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.55.11.1757","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"55","author":"Biraben","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0270","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0035-3787(06)75126-8","article-title":"Exacerbation of tonicoclonic seizures in a juvenile myoclonic epileptic taking lamotrigine","volume":"162","author":"Maiga","year":"2006","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0275","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1684\/epd.2009.0284","article-title":"Myoclonic status epilepticus in juvenile myoclonic epilepsy","volume":"11","author":"Larch","year":"2009","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0280","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/brain\/awl047","article-title":"Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy","volume":"129","author":"Thomas","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0285","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.1985.tb00873.x","article-title":"Long-term study of gamma-vinyl GABA in the treatment of epilepsy","volume":"72","author":"Pedersen","year":"1985","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0290","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.49.5.1467","article-title":"Vigabatrin aggravates absences and absence status","volume":"49","author":"Panayiotopoulos","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0295","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2515\/therapie\/2009033","article-title":"Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate","volume":"64","author":"Crespel","year":"2009","journal-title":"Therapie"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0300","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0305","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e318250d824","article-title":"Effects of fetal antiepileptic drug exposure: outcomes at age 4.5years","volume":"78","author":"Meador","year":"2012","journal-title":"Neurology"},{"issue":"Suppl. 6","key":"10.1016\/j.yebeh.2013.01.001_bb0310","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1111\/j.1528-1157.1996.tb06037.x","article-title":"The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome","volume":"37","author":"Morrell","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0315","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yebeh.2012.03.003","article-title":"Energy drinks and seizures: what is the link?","volume":"24","author":"Ferlazzo","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2013.01.001_bb0320","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.0013-9580.2004.451004.x","article-title":"Visual stimuli in daily life","volume":"45","author":"Kasteleijn-Nolst Trenite","year":"2004","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2013.01.001_bb0325","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1528-1167.2006.00463.x","article-title":"Suppressive efficacy by a commercially available blue lens on PPR in 610 photosensitive epilepsy patients","volume":"47","author":"Capovilla","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0330","series-title":"Epileptic syndromes in Infancy, Chilhood and Adolescence","first-page":"507","article-title":"Photosensitivity and Syndrome","author":"Kasteleijn-Nolst Tr\u00e9nit\u00e9","year":"2012"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0335","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF00242439","article-title":"Impulsiv petit mal","volume":"176","author":"Janz","year":"1957","journal-title":"Dtsch Z Nervenheilkd"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0340","first-page":"297","article-title":"Psychiatric disorders in juvenile myoclonic epilepsy","volume":"157","author":"G\u00e9lisse","year":"2001","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0345","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1528-1167.2006.00828.x","article-title":"Psychiatric comorbidity in juvenile myoclonic epilepsy","volume":"47","author":"Trinka","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0350","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.yebeh.2007.01.016","article-title":"Psychiatric disorders in juvenile myoclonic epilepsy: a controlled study of 100 patients","volume":"10","author":"de Ara\u00fajo Filho","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0355","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.seizure.2010.10.004","article-title":"Prognosis of juvenile myoclonic epilepsy is related to endophenotypes","volume":"20","author":"Guaranha","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0360","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/seiz.2000.0479","article-title":"Adjunctive behavioural treatment in adolescents and young adults with juvenile myoclonic epilepsy","volume":"10","author":"Martinovi\u0107","year":"2001","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0365","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1059-1311(03)00147-X","article-title":"Vagus nerve stimulation for refractory idiopathic generalised epilepsy","volume":"13","author":"Ng","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.2007.00848.x","article-title":"Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy?","volume":"187","author":"Kostov","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0375","first-page":"708","article-title":"Treatment of juvenile myoclonic epilepsy with low-dose sodium valproate","volume":"152","author":"de Toffol","year":"1996","journal-title":"Rev Neurol"},{"key":"10.1016\/j.yebeh.2013.01.001_bb0380","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1528-1157.1993.tb02589.x","article-title":"Seizure threshold in juvenile myoclonic epilepsy with Graves disease","volume":"34","author":"Su","year":"1993","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505013000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505013000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T03:03:44Z","timestamp":1715483024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505013000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":76,"alternative-id":["S1525505013000024"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2013.01.001","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of juvenile myoclonic epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2013.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}